Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

LHBullishM&Anews

High materiality7/10

Labcorp to acquire BioReference Health assets from OPKO for $722 million

Oct 15, 2026, 7:42 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strategic expansion into more testing domains and the 4Kscore asset could elevate near-term prospects and long-term growth; however, material benefits hinge on regulatory close and integration success.

AI summary

What happened, with direct paths to the underlying reporting

Labcorp will acquire BioReference Health's clinical and specialty testing assets, including the 4Kscore Test, for $722 million cash with a potential $150 million earnout. The deal adds 80+ service centers and broadens Labcorp's portfolio in women's health, urology, and diagnostic analytics, with management projecting about $250 million in first-year revenue after closing, subject to regulatory approvals.

Labcorp to acquire BioReference Health assets from OPKO for $722 million.
Earnout up to $150 million tied to 4Kscore Test revenue.
Adds 80+ patient service centers; expands women's health, urology, and corrections testing.
4Kscore Test, FDA-approved, expands access to prostate cancer risk testing nationwide.
First-year revenue expected around $250 million post-close; regulatory approvals required.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.